Venous system anomaly as a reason for misplacement of pacemaker lead (RCD code: IV1C.1)
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2016, Vol 2, Issue 6
Abstract
We present a case of a 45-year old patient with history of surgical ASD II closure and pacemaker implantation who was only recently diagnosed with lead mispalcement due to anomalous venous return.
Authors and Affiliations
Zbigniew Gąsior, Katarzyna Mizia-Stec, Aleksandra Wilczek-Banc, Magdalena Mizia, Wojciech Walkowicz, Krzysztof Gołba, Piotr Pysz
Keywords
Related Articles
- EP ID EP248111
- DOI 10.20418/jrcd.vol2no6.214
- Views 126
- Downloads 0
Giant cell myocarditis: challenge of mechanical circulatory support (RCD code: III-1B.1.o)
We report the case of a young adult male who presented with acute fulminant myocarditis, deteriorated rapidly despite intra‑aortic balloon pump and inotropic support, and received a HeartMate II continuous flow left vent...
Patient with constrictive pericarditis (RCD code: III)
52-year-old Caucasian man was admitted with clinical symptoms of chronic heart failure. Constrictive pericarditis was suspected almost 9 years before admission, but Patient refused to diagnosis. Peripheral oedema, ascite...
Development of the European Network in Orphan Cardiovascular Diseases. EU Project inauguration
Both international and Polish cardiology community warmly welcomed our prior international project entitled Establishing a European Network for Orphan Cardiovascular Diseases (European Regional Development Fund and Małop...
Current views on the use of interferons in the treatment of polycythaemia vera
Interferon alpha is a molecule associated with stimulation of immune system cells, resulting in an anti‐proliferative and immunomodulatory effect. It has been demonstrated that interferon reduces the number of platelets,...
Comparison of platelet count reduction in patients with essential thrombocythaemia treated with hydroxyurea and thromboreductin. Single centre experience
Essential thrombocythemia is one of the Ph-negative myeloproliferative neoplasms treated with hydroxyurea. An alternative strategy may be a therapy with thromboreductin. The aim of the study was to compare the effectiven...